Tepezza (teprotumumab-trbw) / Genmab, Roche, Amgen - LARVOL DELTA

Flare following Teprotumumab Treatment in Thyroid Eye Disease (TED): A Retrospective Cohort Study (ATA 2026) - No abstract available

Retrospective data • Ophthalmology • Thyroid Eye Disease

Durability of Teprotumumab Treatment for Thyroid Eye Disease (ATA 2026) - No abstract available

Ophthalmology • Thyroid Eye Disease

Durability of Response among Teprotumumab Responders with Thyroid Eye Disease (TED): A Retrospective Cohort Study (ATA 2026) - No abstract available

Retrospective data • Ophthalmology • Thyroid Eye Disease

Subsequent Interventions following First-Line Teprotumumab in Thyroid Eye Disease: Findings from a Large Real-World Study in the United States (ATA 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Ophthalmology • Thyroid Eye Disease

Resolution of Pretibial Myxedema with Teprotumumab in Patients with Graves' Disease (ATA 2026) - No abstract available

Clinical • Endocrine Disorders • Grave’s Disease

Therapeutic Effects of Teprotumumab in a Japanese Prospective Cohort: Comparison of MRI Findings with Intravenous Glucocorticoid Therapy (ATA 2026) - No abstract available

Clinical

Salutary Effect of Teprotumumab on Pretibial Myxedema (ATA 2026) - No abstract available

Coexpression of IGF1R and TSHR in extraocular muscles of patients with thyroid-associated orbitopathy. (PubMed, Br J Ophthalmol) - "Our study revealed elevated IGF1R and TSHR expression in the extraocular muscles of patients with TAO, supporting their potential involvement in orbital fibroblast infiltration and muscle remodelling in TAO. These findings provide tissue-based support for the biological relevance of IGF1R in TAO-related extraocular muscle pathology and may help inform future investigations of IGF1R-targeted therapies such as teprotumumab. Further quantitative and mechanistic studies are warranted to better define the therapeutic implications of these findings."

Journal • Fibrosis • Immunology • Ophthalmology • Strabismus • Thyroid Eye Disease • IGF1R • TSHR

Recent advances in the medical management of thyroid eye disease. (PubMed, Curr Opin Endocrinol Diabetes Obes) - "The development of novel targeted medications with expanding therapeutic options may facilitate personalized management of TED in the future."

Journal • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Otorhinolaryngology • Thyroid Eye Disease • IL6

Drug-associated central nervous system vasculitis and reversible cerebral vasoconstriction syndrome: A global disproportionality analysis of the WHO pharmacovigilance database (VigiBase). (PubMed, Br J Clin Pharmacol) - "Drug-associated CNSV and RCVS exhibit distinct pharmacological and temporal profiles, which may help inform drug withdrawal decisions and optimal management of these neurovascular emergencies."

Adverse events • Journal • Oncology • Ophthalmology • Thyroid Eye Disease • Vasculitis

Teprotumumab for dysthyroid optic neuropathy: early functional and structural improvement in a retrospective case series. (PubMed, Endocr J) - "These findings suggest that teprotumumab was associated with early concordant improvement across functional, anatomic, and MRI-based inflammatory endpoints in patients with DON. Careful monitoring, particularly audiologic assessment, remains essential."

Journal • Retrospective data • CNS Disorders • Fatigue • Ocular Inflammation • Ophthalmology • Optic Neuritis • Otorhinolaryngology • Pain • Thyroid Eye Disease

How to manage thyroid eye disease: recent advances - a narrative review. (PubMed, Drugs Context) - "The advent of targeted biologic therapies, particularly teprotumumab, as well as rituximab and tocilizumab, has significantly expanded therapeutic options and enabled a more personalized, phenotype-driven approach. Despite these advances, challenges related to accessibility, cost, long-term safety and optimal patient selection persist. Ongoing research and international collaboration are expected to refine management strategies and enhance the quality of life of patients with TED."

Journal • Review • Endocrine Disorders • Grave’s Disease • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Thyroid Eye Disease

Adjunctive Orbital Radiation Therapy with Teprotumumab in Recalcitrant Thyroid Eye Disease: A Case Report. (PubMed, Ophthalmic Plast Reconstr Surg) - "Following orbital radiation therapy, the patient demonstrated sustained orbital disease stabilization and resolution of compressive optic neuropathy despite recurrence of severe pretibial myxedema and elevated thyroid-stimulating antibodies. This case suggests that adjunctive orbital radiation therapy with teprotumumab may provide durable orbital disease control despite ongoing systemic reactivations and lower the risk of compressive optic neuropathy in high-risk recalcitrant thyroid eye disease, supporting its continued role as a disease-modifying adjunct in select patients."

Journal • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Thyroid Eye Disease

Online medical education can significantly improve physicians’ knowledge, competence and confidence when using targeted immunotherapy for thyroid eye disease (TED) in clinical practice according to guidelines (ETA 2026) - "Additional education is warranted, due to TED therapy with teprotumumab, as the first licensed immunotherapy, not yet being established outside of the US, and low overall knowledge and confidence levels Table 1. Changes in thyroid function and body composition after sleeve gastrectomy. Opth ( n 255) Endo ( n 265) Correct pre Correct post p Correct pre Correct post Knowledge: TED assessment clinical activity score 38% 58% P < .0.01 29% 44% P < .0.01 Knowledge: Patient selection for targeted immunotherapy using EUGOGO guidelines 100% 100% P = 1.0 20% 100% P < .0.05 Competence: Making treatment decisions in TED (improve eye motility using ATA/ETA guidelines) 36% 44% P < .0.01 32% 60% P < .0.01 Competence: Making treatment decisions in TED (identify best proptosis 2L option using evidence guidelines) 42% 73% P < .0.01 44% 77% P < .0.01"

Clinical • Gastrointestinal Disorder • Ophthalmology • Thyroid Eye Disease

Variability Between Changes in Ocular Alignment and Gorman Diplopia Score After Teprotumumab in Thyroid Eye Disease. (PubMed, Neuroophthalmology) - "Teprotumumab improves both ocular alignment and diplopia in most TED patients; however, differences were observed between subjective and objective outcome measures. Validated tools are needed to assess therapeutic outcomes more accurately in TED-related strabismus."

Journal • Myositis • Ophthalmology • Strabismus • Thyroid Eye Disease • IGF1

Teprotumumab for thyroid eye disease-associated superior ophthalmic vein periphlebitis: a case series. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "All patients with TED-associated SOVP demonstrated complete radiologic resolution, with significant reduction in SOV diameter and improvement in disease activity and proptosis, supporting SOVP as a reversible inflammatory manifestation of active TED."

Journal • Inflammation • Ocular Inflammation • Ophthalmology • Thyroid Eye Disease

Trends in Thyroid Eyes Disease incidence and prevalence in France, 2019-23: a nationwide population study (ETA 2026) - "Among the 4,422 incident patients with at least one year of follow-up (UB), 2,083 patients (47.1%) received infusion of intra-DRG (diagnosis related group) IV drugs (likely corresponding to intravenous corticosteroids) while tocilizumab, rituximab and teprotumumab (available through compassionate use program) were used in 214 patients (4.8%), 69 (1.6%) and 27 (0.6%) patients, respectively. This study provides the first nationwide estimates of TED epidemiology in France and a general overview of patients hospitalized for TED in France between 2019 and 2023."

Clinical • Endocrine Disorders • Grave’s Disease • Immunology • Ophthalmology • Strabismus • Thyroid Eye Disease

Case Report: Teprotumumab treatment in an HIV-infected patient with refractory thyroid eye disease: clinical and quantitative MRI evidence. (PubMed, Front Immunol) - "Disease activity recurred after intravenous glucocorticoids and tocilizumab and persisted despite bilateral orbital decompression. The relative dissociation between orbital improvement and conventional systemic immune indices suggests that local IGF-1R-dependent mechanisms may contribute to treatment response. Further studies are required to determine long-term efficacy and safety."

Journal • Endocrine Disorders • Grave’s Disease • Human Immunodeficiency Virus • Immunology • Infectious Disease • Ocular Inflammation • Ophthalmology • Thyroid Eye Disease • CD4 • CD8

Changes in diplopia after teprotumumab therapy in patients with active thyroid eye disease (ETA 2026) - "Teprotumumab therapy improved proptosis and orbital inflammatory findings in patients with active TED. Improvement in diplopia was observed in 50% of patients, although complete resolution was limited. Patients with unilateral extraocular muscle involvement and primary gaze diplopia appeared less likely to achieve full resolution, suggesting that residual ocular deviation may persist despite improvement of orbital inflammation."

Clinical • Inflammation • Ocular Inflammation • Ophthalmology • Thyroid Eye Disease

Teprotumumab Effects on Thyroid Eye Disease in a Japanese MRI Study: Comparison with Intravenous Glucocorticoid Therapy. (PubMed, J Clin Endocrinol Metab) - "TEP showed robust effectiveness in Japanese real-world patients with TED. MRI-based analyses revealed distinct effects of TEP and IVGC on orbital fat and identified inflamed extraocular muscles as treatment-responsive components."

Journal • Ophthalmology • Thyroid Eye Disease

Clinical and magnetic resonance imaging outcomes of teprotumumab in a Japanese thyroid eye disease cohort: comparison of patients with and without dysthyroid optic neuropathy. (PubMed, Can J Ophthalmol) - "Teprotumumab demonstrated significant clinical and radiologic efficacy in patients with active TED, including those with DON. MRI revealed marked reductions in orbital inflammation and EOM enlargement after treatment, supporting the value of MRI as an objective tool for assessing disease activity and treatment response."

Journal • Inflammation • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Thyroid Eye Disease

Reduction in extraocular muscle and orbital fat volumes after teprotumumab treatment in Japanese patients with thyroid eye disease: an exploratory magnetic resonance imaging analysis from the OPTIC-J trial. (PubMed, Jpn J Ophthalmol) - "In this OPTIC-J trial substudy, reductions in orbital soft tissue volumes and inflammation/edema were observed with MRI after teprotumumab treatment vs placebo; corresponding improvements in TED clinical outcomes were also observed."

Journal • Inflammation • Ocular Inflammation • Ophthalmology • Thyroid Eye Disease

A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease (clinicaltrials.gov) - P4 | N=92 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2027 ➔ Dec 2028 | Initiation date: Dec 2025 ➔ Jul 2026 | Trial primary completion date: Sep 2026 ➔ Jun 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Ophthalmology • Thyroid Eye Disease

Hearing loss in hyperthyroid patients treated with teprotumumab (TepezzaR). (PubMed, Eur Arch Otorhinolaryngol) - "Teprotumumab use is associated with a significantly increased risk of sensorineural and unspecified hearing loss in patients with hyperthyroidism. These findings support routine audiologic monitoring during treatment and highlight the need for prospective studies to investigate underlying mechanisms and preventative strategies."

Journal • Endocrine Disorders • Otorhinolaryngology

Infographic: a randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients. (PubMed, Eye (Lond)) - No abstract available

Journal • Ophthalmology • Thyroid Eye Disease